2025;
Fidelito G, Todorovski I, Cluse L, Vervoort SJ, Taylor RA, Watt MJ. Lipid-metabolism-focused CRISPR screens identify enzymes of the mevalonate pathway as essential for prostate cancer growth. Cell Reports. 2025;44(4):10.1016/j.celrep.2025.115470
Lelliott EJ, Naddaf J, Ganio K, Michie J, Wang S, Liu L, Silke N, Ahn A, Ramsbottom KM, Brennan AJ, Freeman AJ, Goel S, Vervoort SJ, Kearney CJ, Beavis PA, McDevitt CA, Silke J, Oliaro J. Intracellular zinc protects tumours from T cell-mediated cytotoxicity. Cell Death & Differentiation. 2024;31(12):10.1038/s41418-024-01369-4
Costacurta M, Sandow JJ, Maher B, Susanto O, Vervoort SJ, Devlin JR, Garama D, Condina MR, Steele JR, Kahrood HV, Gough D, Johnstone RW, Shortt J. Mapping the IMiD‐dependent cereblon interactome using BioID‐proximity labelling. The FEBS Journal. 2024;291(22):10.1111/febs.17196
Todorovski I, Tsang M-J, Feran B, Fan Z, Gadipally S, Yoannidis D, Kong IY, Bjelosevic S, Rivera S, Voulgaris O, Zethoven M, Hawkins ED, Simpson KJ, Arnau GM, Papenfuss AT, Johnstone RW, Vervoort SJ. RNA kinetics influence the response to transcriptional perturbation in leukaemia cell lines. NAR Cancer. 2024;6(4):10.1093/narcan/zcae039
Djajawi TM, Wichmann J, Vervoort SJ, Kearney CJ. Tumor immune evasion: insights from CRISPR screens and future directions. The FEBS Journal. 2024;291(7):10.1111/febs.17003
Djajawi TM, Pijpers L, Srivaths A, Chisanga D, Chan KF, Hogg SJ, Neil L, Rivera SM, Bartonicek N, Ellis SL, Lim Kam Sian TCC, Faridi P, Liao Y, Pal B, Behren A, Shi W, Vervoort SJ, Johnstone RW, Kearney CJ. PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity. Cell Reports. 2024;43(3):10.1016/j.celrep.2024.113831
House IG, Derrick EB, Sek K, Chen AXY, Li J, Lai J, Todd KL, Munoz I, Michie J, Chan CW, Huang Y-K, Chan JD, Petley EV, Tong J, Nguyen D, Engel S, Savas P, Hogg SJ, Vervoort SJ, Kearney CJ, Burr ML, Lam EYN, Gilan O, Bedoui S, Johnstone RW, Dawson MA, Loi S, Darcy PK, Beavis PA. CRISPR-Cas9 screening identifies an IRF1-SOCS1-mediated negative feedback loop that limits CXCL9 expression and antitumor immunity. Cell Reports. 2024;43(2):10.1016/j.celrep.2024.113793
House IG, Derrick EB, Sek K, Chen AXY, Li J, Lai J, Todd KL, Munoz I, Michie J, Chan CW, Huang Y-K, Chan JD, Petley EV, Tong J, Nguyen D, Engel S, Savas P, Hogg SJ, Vervoort SJ, Kearney CJ, Burr ML, Lam EYN, Gilan O, Bedoui S, Johnstone RW, Dawson MA, Loi S, Darcy PK, Beavis PA. CRISPR-Cas9 screening identifies an IRF1-SOCS1-mediated negative feedback loop that limits CXCL9 expression and antitumor immunity. Cell Reports. 2023;42(8):10.1016/j.celrep.2023.113014
Peeters JGC, Boltjes A, Scholman RC, Vervoort SJ, Coffer PJ, Mokry M, Vastert SJ, van Wijk F, van Loosdregt J. Epigenetic changes in inflammatory arthritis monocytes contribute to disease and can be targeted by JAK inhibition. Rheumatology. 2023;62(8):10.1093/rheumatology/kead001
